The Biotechnology Innovation Organization (BIO) is pleased to submit a statement for the record to the United States House of Representatives Committee on Agriculture hearing entitled, “A 2022 Review of the Farm Bill: Energy- Renewable Energy Opportunities in Rural America.”

The Biotechnology Innovation Organization (BIO) is pleased to submit these comments in response to the U.S. Environmental Protection Agency’s (EPA’s) February 28-March 1, 2022, workshop on biofuel greenhouse gas modeling.

The Biotechnology Innovation Organization (BIO) appreciates the opportunity to comment on the Oregon Health Authority’s (OHA) proposed Oregon Health Plan §1115 Demonstration Waiver Application (Waiver Application), which among other things, would be a waiver of compliance with essential provisions of §1927 of the Social Security Act (SSA) to exclude drugs approved through the FDA’s accelerated approval pathway (AAP). We urge CMS to reject those provisions of the proposed waiver that would exacerbate health disparities and jeopardize patient access and care, especially for patients with rare and chronic diseases.